Company / Accounts Receivable
CRISPR Therapeutics AG Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
-
FY2025
5-year range
$0 / $200.0M
FY2021-FY2025
Trend
-100.0%
vs FY2024
Sector context
#115 of 115
Health Care
What the data says
Declined from $200M to $0 over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 0% in Health CareTop 100% of 115
▼
Key checks
Key Insights
- In FY2025, accounts receivable decreased 100.0% year-over-year.
- Peak accounts receivable was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0 | -100.0% |
| FY2024 | $25.0M | -87.5% |
| FY2023 | $200.0M | - |
| FY2022 | $0 | -100.0% |
| FY2021 | $305.0K | +111.8% |
| FY2020 | $144.0K | +45.5% |
| FY2019 | $99.0K | +12.5% |
| FY2018 | $88.0K | -96.6% |
| FY2017 | $2.6M | -16.8% |
| FY2016 | $3.2M | +831.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026